These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 14723556)

  • 1. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.
    Abdel-Hamid IA
    Drugs; 2004; 64(1):13-26. PubMed ID: 14723556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
    Wang WF; Minhas S; Ralph DJ
    Int J Androl; 2006 Oct; 29(5):503-09. PubMed ID: 16573707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.
    Chen J; Keren-Paz G; Bar-Yosef Y; Matzkin H
    Eur Urol; 2007 Nov; 52(5):1331-9. PubMed ID: 17728050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation.
    Uckert S; Bazrafshan S; Sonnenberg JE; Kuczyk MA
    J Sex Med; 2009 Feb; 6(2):408-14. PubMed ID: 19040619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].
    Mo DS; Shang XJ; Huang YF
    Zhonghua Nan Ke Xue; 2015 Jun; 21(6):561-5. PubMed ID: 26242050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.
    Gökçe A; Halis F; Demirtas A; Ekmekcioglu O
    BJU Int; 2011 Apr; 107(8):1274-7. PubMed ID: 21929518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone therapy in erectile dysfunction and hypogonadism.
    Shabsigh R
    J Sex Med; 2005 Nov; 2(6):785-92. PubMed ID: 16422803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation.
    Chen J; Mabjeesh NJ; Matzkin H; Greenstein A
    Urology; 2003 Jan; 61(1):197-200. PubMed ID: 12559295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire.
    el-Sakka AI
    Urology; 2006 Sep; 68(3):642-7. PubMed ID: 16979718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide.
    Kalsi JS; Ralph DJ; Thomas P; Bellringer J; Minhas S; Kell PD; Cellek S
    J Sex Med; 2005 Jan; 2(1):53-7. PubMed ID: 16422907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of phosphodiesterase 5 inhibitors.
    Carrier S
    Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of sildenafil citrate for infertile men with sexual dysfunction: a pilot study.
    Boorjian S; Hopps CV; Ghaly SW; Parker M; Mulhall JP
    BJU Int; 2007 Sep; 100(3):603-6. PubMed ID: 17590181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.